Stephen A. Munk

Stephen A. Munk, Ph.D.

President & CEO

Stephen Munk, Ph.D. is President and CEO of Ash Stevens Inc. Since joining the company in 1997, Ash Stevens has received 10 FDA approvals to manufacture innovator drug substance and won four NIH research contacts, including two competing renewals. Prior to joining Ash Stevens, Dr. Munk worked at Allergan, Inc. – initially as a drug discovery scientist and subsequently as co-team leader of the adrenergic drug discovery team responsible for the commercialization of Brimonidine Tartrate (API in glaucoma treatment Alphagan®). He earned his Ph.D. at UC Berkeley under the supervision of Henry Rapoport and completed an American Cancer Society Postdoctoral Fellowship with Dale Boger at Purdue.

Dr. Munk’s work has been summarized in 35 publications and patents. He serves as an Adjunct Professor of Chemistry at Wayne State University, on the Board of Directors of MichBio, chairs the Steering Committee of the Chemistry in Cancer Research Working Group of the American Association for Cancer Research (2014), and served a three-year term on the Board of Governors of SOCMA.

Back to Top

Dr. James M. Hamby

Dr. James M. Hamby

Vice President, Business Development

Dr. Hamby is an experienced scientist and businessman in the area of small-molecule drug discovery and development. Since joining Ash Stevens, Inc. (ASI) in 2006, Dr. Hamby has helped grow and position the company as a preferred supplier of high quality contract drug development and manufacturing services. Dr. Hamby is responsible for new business activities and marketing for the company.

Dr. Hamby received his B.S. degree in Pharmacy and Ph.D. degree in Medicinal Chemistry from the University of Illinois College of Pharmacy in Chicago. Before joining ASI, Dr. Hamby spent two years as a post-doctoral fellow at Princeton University and eighteen years in drug discovery research at Warner-Lambert/Parke-Davis and Pfizer in Ann Arbor Michigan. Dr. Hamby has over 35 publications and twenty patents.

Back to Top

vince Ammoscato

Mr. Vince Ammoscato

Vice President, Operations

Vince Ammoscato is Vice President of Operations at Ash Stevens, serving as the primary technical contact between the company and its clients. He has over 24 years of hands-on technical experience and extensive knowledge of the regulatory requirements for API development and manufacturing. Mr. Ammoscato manages all of the technical disciplines needed to fulfill the requirements of the CMC section of an IND/NDA at Ash Stevens.

He has extensive experience in multi-step regio- and stereoselective synthesis, including synthesis of Nucleosides, Peptide based compounds, and Heterocycles. He was previously a process development scientist at Ash Stevens, involved the development, manufacture and project management of multiple new chemical entities from preclinical development through commercialization. These included Fludarbine Phosphate (Fludara®), Floxuridine, Bortezomib (Velcade®), and Ponatinib.HCl (Iclusig®), which were all approved by the FDA and other MoHs as treatments for various forms of cancer.

Mr. Ammoscato earned a B.Sc. in Chemistry (1988) and a M.Sc. in Organic Chemistry (1990) at the University of Windsor, Canada. He joined Ash Stevens as a Senior Process Development Scientist (1990-2004) and subsequently Director, Project Management (2004-2009) before moving into his current role.

Back to Top


Ash Stevens has two facilities for development and manufacture of APIs located in the State of Michigan.

Ash Stevens Vision

To translate scientific discoveries into medicinal products that improve quality of life.